Skip to main content
SpringerLink
Log in

Denosumab: ONJ and hypocalcaemia ADR updates in EU

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bellamy S. Denosumab 60mg (Prolia): Updated information to minimise the risk of osteonecrosis of the jaw and hypocalcaemia. Internet Document : [3 pages], 26 Aug 2014. Available from: URL: http://www.mhra.gov.uk/home/groups/comms-ic/documents/drugsafetymessage/con454359.pdf

  2. Bellamy S. Denosumab 120mg (XGEVA): Updated information to minimise the risk of osteonecrosis of the jaw and hypocalcaemia. Internet Document : [4 pages], 26 Aug 2014. Available from: URL: http://www.mhra.gov.uk/home/groups/comms-ic/documents/drugsafetymessage/con454360.pdf

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Denosumab: ONJ and hypocalcaemia ADR updates in EU. Reactions Weekly 1519, 1 (2014). https://doi.org/10.1007/s40278-014-3420-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-3420-y

Search

Navigation